Aeon Biopharma Inc.
AEON
AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox (onabotulinumtoxinA) with the goal of achieving full-label United States ( U.S. ) market entry for debilitating medical conditions. On December 12, 2022, AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc.) ( Old AEON ) and Priveterra Merger Sub, Inc., a wholly own…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$48M
▼ -193.4% YoY
Op. Margin
–
ROIC
-148.04%
▼ -143.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$17M
▲ +14.7% YoY
Op. Cash Flow (TTM)
-$17M
▲ +14.7% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$11M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with AEON
Aeon Biopharma (AEON) in two numbers
Questions about Aeon Biopharma
Does Aeon Biopharma (AEON) pay a dividend?
No. Aeon Biopharma (AEON) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 13 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in AEON's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AEON
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.